Incidence and Timing of Abacavir Hypersensitivity Reaction
Abacavir hypersensitivity reaction is a multi-organ systemic illness that in the era prior to testing with HLA-B*5701 occurred in approximately 5 to 8% of HIV-infected patients who initiated therapy with abacavir.[,] The abacavir hypersensitivity reaction resembles a delayed hypersensitivity reaction and it can cause life-threatening complications if abacavir is continued despite progressive symptoms. In addition, among persons who have experienced the abacavir hypersensitivity reaction, subsequent rechallenge with abacavir following discontinuation can cause an immediate and potentially fatal reaction. This hypersensitivity reaction can occur with any of the following medications: abacavir (Ziagen), abacavir-lamivudine (Epzicom), zidovudine-lamivudine-abacavir (Trizivir), and abacavir-lamivudine-dolutegravir (Triumeq). The incidence of abacavir hypersensitivity reported in clinical trials involving predominantly Caucasians is approximately 6 to 8% (range 2 to 9%).[,] In contrast, the risk among African Americans is significantly lower and is approximately 2 to 3%. More than 90% of abacavir hypersensitivity reactions occur during the first 6 weeks of therapy, with a median time to onset of symptoms of 9 days.[,,] Failure to recognize the reaction has been associated with fatalities when abacavir was continued despite progressive symptoms. In multivariate analysis, the risk of developing hypersensitivity was almost 40% lower for individuals of African descent and for patients with prior antiretroviral experience. There has been no clear correlation of the risk of abacavir hypersensitivity with the baseline CD4 cell count or HIV-1 RNA level.
HLA-B*5701 and Hypersensitivity Reaction
In 2002, investigators first described an association of abacavir hypersensitivity with the genetic markers HLA-B*5701, HLA-DR7, and HLA-DQ3 in cohorts composed predominantly of Caucasian men; the presence of all three of the markers—HLA-B*5701, HLA-DR7, and HLA-DQ3—had a positive predictive value for abacavir hypersensitivity of 100% and a negative predictive value of 97% (Figure 1). Subsequent studies have shown HLA-B*5701 alone serves as an excellent predictor of abacavir hypersensitivity syndrome.[,,,] In one study, 260 abacavir-naive patients were prospectively sorted into low-risk and high-risk hypersensitivity groups based on HLA-B*5701 status and no cases of abacavir hypersensitivity were identified in the 148 HLA-B*5701-negative patients treated with abacavir. In the PREDICT-1 trial, a multinational study that involved 1956 mostly Caucasian patients from 19 countries, patients were randomized to either prospective HLA-B*5701 screening (patients with positive HLA-B*5701 did not receive abacavir) or to the standard of care (no screening and all patients received abacavir). Among the 802 individuals who screened negative for HLA-B*5701, 3.4% had a clinical diagnosis of abacavir hypersensitivity reaction, but 0% had immunologically confirmed abacavir hypersensitivity using patch testing. The retrospective Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation (SHAPE) study confirmed the lower risk of abacavir hypersensitivity reaction in blacks and reinforced the value of HLA-B*5701 screening in both white and black populations. In another study, investigators examined the risk of abacavir hypersensitivity in racially-diverse North American population of patients who had a negative HLA-B*5701 screening test and found that 4 (0.8%) of 517 patients developed suspected abacavir hypersensitivity syndrome within 6 weeks of starting abacavir.
Clinical and Laboratory Manifestations
The abacavir hypersensitivity reaction is a multi-organ process manifested by at least two of the following signs or symptoms: (1) fever, (2) rash, (3) gastrointestinal, (4) constitutional, or (5) respiratory. In contrast to the more prominent rash that can develop with sulfonamides or the non-nucleoside reverse transcriptase inhibitors (NNRTIs), the rash associated with abacavir is often mild and is usually not the predominant symptom. With the abacavir hypersensitivity reaction, constitutional symptoms (fatigue, myalgias, and generalized malaise) are often present, and some patients may have prominent respiratory symptoms, such as dyspnea, cough, and pharyngitis. The constellation of symptoms associated with abacavir hypersensitivity are often non-specific, frequently mimicking those of viral illnesses such as influenza. Investigators compared 15 patients with abacavir hypersensitivity with 30 patients with culture proven influenza A (and no abacavir exposure) and found gastrointestinal symptoms strongly correlated with abacavir hypersensitivity, whereas cough without gastrointestinal symptoms correlated with influenza (Figure 2). In general, the probability of abacavir hypersensitivity increases when a greater number of manifestations are present (Figure 3). Other important diagnostic clues, are the accentuation of symptoms within hours of taking each dose of abacavir and the escalation of symptoms with each subsequent dose. Abnormal laboratory findings are nonspecific, but may include leukopenia, anemia, thrombocytopenia, as well as elevations in aminotransferase levels, blood urea nitrogen, creatinine, and lactate dehydrogenase. Eosinophilia is usually not present.[,] In most patients, stopping abacavir will promptly result in resolution of symptoms caused by the abacavir hypersensitivity reaction.
Rechallenge with Abacavir
In patients who have experienced abacavir hypersensitivity reaction, rechallenge with abacavir has been associated with severe, life-threatening reactions manifested by hypotension, renal insufficiency, and bronchoconstriction. During the early drug development of abacavir, patients with abacavir hypersensitivity were rechallenged, and immediate life-threatening reactions occurred in approximately 20% of these individuals. Now, medical providers know never to rechallenge an individual who develops an abacavir hypersensitivity reaction. Although a life-threatening reaction has also been reported after restarting abacavir in the absence of preceding hypersensitivity, this appears to be an extremely rare event. Moreover, subsequent studies have found no increase in hypersensitivity risk after abacavir treatment interruptions in the absence of a preceding hypersensitivity reaction.[,]
HLA-B*5701 Screening Recommendations
The most important aspect of clinical care related to the abacavir hypersensitivity reaction is the use of effective prevention measures. Accordingly, the Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents recommends screening for HLA-B*5701 before starting any patient on any abacavir-containing regimen. This panel has also recommended that any patient with a positive test for HLA-B*5701 should not receive abacavir. Further, a positive test for HLA-B*5701 should prompt documentation of an abacavir allergy in the patient's chart. Use of HLA-B*5701 as a screening test for abacavir hypersensitivity reaction has become the standard of care in the United States. Although the HLA-B*5701 is an excellent screening tool for abacavir hypersensitivity, a negative test does not absolutely rule out a possible abacavir hypersensitivity reaction. The most widely used screening test uses a polymerase chain reaction sequence-specific oligonucleotide probe for the genetic sequences that code for the HLA-B*570 allele; the test is usually performed on a blood or saliva sample. In the setting where HLA-B*5701 screening is not readily available, the panel suggests that it is reasonable to initiate therapy with abacavir if the patient will receive appropriate clinical counseling and monitoring for any signs of abacavir hypersensitivity reaction. Investigators have shown that prospective screening with the HLA-B*5701 test prior to starting abacavir produces cost savings. The epicutaneous abacavir patch test has been studied as a means to immunologically confirm an abacavir hypersensitivity reaction.[,] Given that a positive patch test should only occur in persons who have previously taken abacavir and developed a hypersensitivity reaction, the patch test is not an appropriate screening test for abacavir hypersensitivity in persons who have never taken abacavir. In addition, at this point, the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents does not recommend using the abacavir patch test as a clinical tool to immunologically confirm an abacavir hypersensitivity reaction.
Management of A Potential Hypersensitivity Reaction
Clear communication with patients and vigilance in recognizing the constellation of symptoms associated with abacavir hypersensitivity reactions are key to effective management. Counseling regarding the hypersensitivity reaction prior to starting abacavir is important, and patients should know when and where to call if they have any symptoms that suggest an abacavir hypersensitivity reaction. The most problematic decision for clinicians occurs when a patient develops mild symptoms that may suggest abacavir hypersensitivity. When it is not clear whether the patient is experiencing an abacavir hypersensitivity reaction, some experts have advised that it is reasonable to have the patient take another dose of the drug and report back within several hours to determine whether the symptoms have progressed. If the symptoms worsen, abacavir should be discontinued. If the symptoms do not worsen, it is reasonable to continue abacavir with extremely close follow-up. The clinician should permanently discontinue abacavir if they cannot rule out the hypersensitivity reaction. If the hypersensitivity reaction occurs, abacavir should be discontinued and supportive care provided. After withdrawal of abacavir, symptoms usually resolve within a few days. In some patients symptoms continue to accelerate for several days after discontinuing abacavir. Corticosteroids have no proven benefit in the management or prevention of the hypersensitivityreaction. Because of the potential for life-threatening rechallenge reactions, individuals who experience hypersensitivity to abacavir must be counseled never to take this drug again. In addition, both medical providers and patients must be aware that the patient cannot use abacavir in the form of Ziagen,Trizivir, Epzicom, or Triumeq.